About EndObetes
EndObetes is a Healthcare company based in New York (United States) founded in 2015 by Marc Bessler. Surgical access tool for obesity and diabetes treatment is developed. EndObetes offers products and services including Endoscopic Devices. Its focus areas include Life Sciences, Obesity, Medical Devices and Therapeutic Devices. Its competitors include Fractyl, GI Windows and Eximis Surgical; 3 of its 3 listed competitors have raised funding.
Company details
EndObetes was founded in 2015 in New York, United States, within the medical device sector focused on gastrointestinal interventions. A surgical access tool has been created to address obesity and diabetes through endoscopic delivery. The device is positioned in the GI tract to route undiluted food directly to the small intestine, replicating gastric bypass effects. Operations center on tool development and potential clinical applications in bariatric care.
- Headquarters New York, United States
- Founders Marc Bessler
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website endobetes.com
- Latest Funding Round$250.59K (USD), Grant
Jul 2020
- InvestorsHHS
& 2 more
Products & Services of EndObetes
EndObetes offers a comprehensive portfolio of products and services, including Endoscopic Devices.
Non-surgical devices for obesity and diabetes management through GI tract fixation.
Funding Insights of EndObetes
- Total Rounds 3
- Last Round Grant — $250,585
- Investors Count 3
All 3 funding rounds of EndObetes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $250,585 | Grant | – | – | |
| Jul 2019 | Seed | – | Biotechnology Innovation Organization | – | |
| Jun 2019 | Seed | – | MedTech Innovator | – |
3 investors in total: 3 institutional.
Investors in EndObetes
EndObetes has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Biotechnology Innovation Organization and MedTech Innovator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Acceleration of medical device, digital health, and diagnostic companies is facilitated worldwide. | medtechinnovator.org | |||
Consulting in business development and communication is provided for biopharma. | 1993 | bio.org | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for EndObetes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EndObetes
1 people are tracked at EndObetes (1 in leadership).
| Name | Role | Group |
|---|---|---|
Marc Bessler | Founder | Leadership |
Complete people profiles for EndObetes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EndObetes
3 dated milestones of EndObetes across 5 years, from founding to its latest funding, stage changes and deals.
- Founded EndObetes is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $251K.
Competitors of EndObetes
EndObetes has 3 listed competitors in our database, 3 of them funded. They include Fractyl, GI Windows and Eximis Surgical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| fractyl.com | 2010 | Lexington, United States | $345.27M | 79 | Endoscopic procedures for type-2 diabetes treatment are developed. | |
| giwindows.com | 2012 | West Bridgewater, United States | $91.98M | 15 | Nonsurgical endoscopic devices for GI tract anastomoses are developed. | |
| eximissurgical.com | 2014 | Louisville, United States | $40.64M | Minimal invasive specimen removal tools |
Detailed competitors of EndObetes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as EndObetes (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EndObetes
EndObetes was founded in 2015 and raised its 1st funding round 4 years after it was founded.
EndObetes is headquartered in New York, United States. It is registered at New York, New York, United States.
EndObetes was founded in 2015 in New York, United States, within the medical device sector focused on gastrointestinal interventions. A surgical access tool has been created to address obesity and diabetes through endoscopic delivery. The device is positioned in the GI tract to route undiluted food directly to the small intestine, replicating gastric bypass effects. Operations center on tool development and potential clinical applications in bariatric care.
EndObetes's top competitors include Fractyl, GI Windows and Eximis Surgical.
EndObetes offers Endoscopic Devices.
EndObetes has 3 investors. Key investors include HHS, Biotechnology Innovation Organization, and MedTech Innovator.